Navigation Links
Cepheid Announces Preliminary 2013 Second Quarter Results
Date:7/11/2013

ical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to revenues and earnings per share for the Second Quarter, projected future revenues for both the Third Quarter and Fiscal Year 2013, consistency of product availability and delivery, sales organization productivity, improving gross margins, execution of manufacturing operations, product sales under the High Burden Developing Country (HBDC) program, commercial test and commercial system sales, and resolution of manufacturing scale-up issues.  Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our Second Quarter review process is not yet completed and actual Second Quarter results are subject to our standard quarterly close and review process; our ability to secure sufficient cartridge parts and increase manufacturing throughput of our cartridge production; our ability to manage our inventory levels; long sales cycles and variability in systems placements and reagent pull-through in the Company's HBDC program; our success in increasing commercial and HBDC sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand, customer confidence in product availability and available capital budgets for our customers; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rat
'/>"/>
SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid Welcomes Executive Vice President of Global Operations
2. Cepheid Reports 2013 First Quarter Results
3. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
4. Cepheid Announces Board of Directors Changes
5. Cepheid Reports 2012 Second Quarter Results
6. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
7. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
8. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
9. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
10. Cepheid to Webcast Upcoming Financial Presentations
11. Cepheid Reports Fourth Quarter and Full Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Widespread use of nanoscale silver will challenge regulatory ... possibility of significant environmental risk, highlighting the need ... according to a new report released today by ... But existing information about the impact of silver ...
... Inc., (TSX:,ARI), a biotechnology company discovering and developing ... RiskMetrics ISS Canada,Canada,s leading independent proxy firm, has ... and are recommending that ARIUS shareholders,and warrant holders ... Roche,will acquire all of ARIUS, outstanding shares and ...
... NewsRx, a 25-year-old publisher and,international news organization headquartered ... and psychiatry/psychology., These new titles will cover ... news and developments in pediatric,and psychiatric medicine. The ... print or online at http://www.NewsRx.com . ...
Cached Biology Technology:Nanoscale silver: No silver lining? 2Nanoscale silver: No silver lining? 3Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche 2Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche 3NewsRx Adds Pediatrics and Psychiatry Titles 2
(Date:4/23/2014)... and German . ... the difference between sexes depends on one single element of the ... the two sexual chromosomes are X and Y, whereas women have ... the morphological and physiological differences between males and females. , But ... ago, the X and Y were identical, until the Y started ...
(Date:4/23/2014)... ripping open a dinner roll, a fuel cell catalyst ... hydrogen molecule. Now researchers have captured a view of ... its hydrogen feast. The view confirms previous hypotheses and ... better for alternative energy uses. , This study is ... hydrogen halves end up in the structure of a ...
(Date:4/23/2014)... is available in French and Spanish ... 23 April 2014Today, the CEC released its Conservation Assessment ... Approach to Conservation, which identifies 29 priority conservation areas ... includes 11 different protected areas in the states of ... diverse arid and semi-arid habitats inhabited by rare and ...
Breaking Biology News(10 mins):Male or female? 2Male or female? 3Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3
... in French . , A study led ... between individuals at the DNA level can lead to ... in turn, are responsible for the vast array of ... of the Genome Regulators in Disease (GRID) Project funded ...
... the elixir of all life, water is a very unusual ... water apart from other solids and liquids commonly found in ... freezes -- an effect known to anyone whose plumbing has ... long list of special characteristics. (Most liquids contract when they ...
... CREEK, CA--A preliminary assembly and annotation of the soybean ... U.S. Department of Energy Joint Genome Institute (DOE JGI), ... The announcement was made by Eddy Rubin, DOE ... the Plant and Animal Genome XVI Conference in San ...
Cached Biology News:Tiny genetic differences have huge consequences: McGill researchers 2Weird water: Discovery challenges long-held beliefs about water's special properties 2Weird water: Discovery challenges long-held beliefs about water's special properties 3DOE JGI releases soybean genome assembly to enable worldwide bioenergy research efforts 2DOE JGI releases soybean genome assembly to enable worldwide bioenergy research efforts 3
... 2000 instrument can be used as a ... Data Manager Software provides the means to ... the instrument. These data can then be ... such as Microsoft Excel or Lotus 123, ...
... allows for quick and reproducible immunoprecipitation (IP) by ... is more reproducible than regular IPs, which are ... agarose without disrupting the agarose bed. The binding ... is reversible, and elution of the immune complex ...
... description: self locking design in ice/water ... new product number, created to easily ... no availability yet, please order under ... contact customer service for assistance. ID ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
Biology Products: